Notizie AIOM – anno XVI n. 678
FDA Grants Priority Review to Gilteritinib for FLT3+ AML
May 29, 2018 - The FDA has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer ...Leggi tutto
FDA Grants Frontline Eltrombopag Priority Review for Severe Aplastic Anemia
May 30, 2018 - The FDA has granted a priority review to a supplemental new drug application (sNDA) for eltrombopag for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia (SAA), according to Novartis, ...Leggi tutto